GSK plc GSK reported third-quarter 2025 core earnings of $1.48 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.26. Core earnings increased 11% year over year on a ...

Banham Zoo keepers spent three years getting 16-year-old Mahiri to use her inhaler confidently Banham Zoo/Facebook Banham Zoo's 16-year-old giraffe, Mahiri, is believed to be the first giraffe in the ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

GRAND RAPIDS, Mich. (WOOD) — Many people manage their asthma with an inhaler — but they may not be using it correctly. Studies show that nearly 90% of patients with an inhaler make at least one ...

Introduction: A well-designed, protocol-driven randomized controlled trial (RCT) has demonstrated the efficacy of fluticasone furoate-umeclidinium-vilanterol (FF-UMEC-VI) in patients with asthma, but ...

1. In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was not associated with improved clinical outcomes compared to receiving ...

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Incruse Ellipta (umeclidinium) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). The drug comes as a dry powder that you inhale. It’s typically used once per ...

After over a decade without notable progress in treating chronic obstructive pulmonary disease, patients with this ongoing condition now have two new treatment options, with more expected in the ...